LVRNA012

LVRNA012 is an mRNA-based vaccine developed as a booster for the prevention of COVID-19, specifically targeting the Omicron BA.5 variant of SARS-CoV-2. It is designed for adults who have previously received two or three doses of inactivated COVID-19 vaccines and are infection-free at the time of administration. The vaccine encodes the spike protein of the Omicron BA.5 variant, prompting host cells to produce this antigen and thereby stimulating an immune response that includes robust production of neutralizing antibodies against both Omicron BA.5 and XBB subvariants. In phase 3 clinical trials conducted in China, a single intramuscular dose (100 μg) demonstrated a protective efficacy of 51.9% against symptomatic COVID-19 compared to placebo over a follow-up period extending up to 180 days post-vaccination during an Omicron/XBB-predominant period[1][2][6]. The immunogenicity profile showed significantly increased neutralizing antibody titers against XBB.1.5 after vaccination[1][2]. Most adverse reactions were mild or moderate in severity[1][2].

Brand names

LVRNA012LVRNA-012LVRNA 012

Other names

SARS-CoV-2 Variant (Omicron BA.5) mRNA VaccineOmicron BA.5 mRNA COVID-19 vaccine